JP2019194191A5 - - Google Patents

Download PDF

Info

Publication number
JP2019194191A5
JP2019194191A5 JP2019103598A JP2019103598A JP2019194191A5 JP 2019194191 A5 JP2019194191 A5 JP 2019194191A5 JP 2019103598 A JP2019103598 A JP 2019103598A JP 2019103598 A JP2019103598 A JP 2019103598A JP 2019194191 A5 JP2019194191 A5 JP 2019194191A5
Authority
JP
Japan
Prior art keywords
composition
viloxazine
pharmaceutically acceptable
acceptable salt
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019103598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019194191A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019194191A publication Critical patent/JP2019194191A/ja
Publication of JP2019194191A5 publication Critical patent/JP2019194191A5/ja
Pending legal-status Critical Current

Links

JP2019103598A 2010-04-12 2019-06-03 ビロキサジン塩を製造する方法及びその新規な多形 Pending JP2019194191A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32315110P 2010-04-12 2010-04-12
US61/323,151 2010-04-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016199937A Division JP2017039754A (ja) 2010-04-12 2016-10-11 ビロキサジン塩を製造する方法及びその新規な多形

Publications (2)

Publication Number Publication Date
JP2019194191A JP2019194191A (ja) 2019-11-07
JP2019194191A5 true JP2019194191A5 (cg-RX-API-DMAC7.html) 2020-01-09

Family

ID=44065289

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2013505028A Active JP6196551B2 (ja) 2010-04-12 2011-04-12 ビロキサジン塩を製造する方法及びその新規な多形
JP2015141683A Pending JP2016006062A (ja) 2010-04-12 2015-07-15 ビロキサジン塩を製造する方法及びその新規な多形
JP2016199937A Pending JP2017039754A (ja) 2010-04-12 2016-10-11 ビロキサジン塩を製造する方法及びその新規な多形
JP2017227668A Active JP6663413B2 (ja) 2010-04-12 2017-11-28 ビロキサジン又はその薬学的に許容される塩を製造する方法
JP2019103598A Pending JP2019194191A (ja) 2010-04-12 2019-06-03 ビロキサジン塩を製造する方法及びその新規な多形

Family Applications Before (4)

Application Number Title Priority Date Filing Date
JP2013505028A Active JP6196551B2 (ja) 2010-04-12 2011-04-12 ビロキサジン塩を製造する方法及びその新規な多形
JP2015141683A Pending JP2016006062A (ja) 2010-04-12 2015-07-15 ビロキサジン塩を製造する方法及びその新規な多形
JP2016199937A Pending JP2017039754A (ja) 2010-04-12 2016-10-11 ビロキサジン塩を製造する方法及びその新規な多形
JP2017227668A Active JP6663413B2 (ja) 2010-04-12 2017-11-28 ビロキサジン又はその薬学的に許容される塩を製造する方法

Country Status (8)

Country Link
US (7) US9403783B2 (cg-RX-API-DMAC7.html)
EP (1) EP2558437B1 (cg-RX-API-DMAC7.html)
JP (5) JP6196551B2 (cg-RX-API-DMAC7.html)
AU (1) AU2011240773C1 (cg-RX-API-DMAC7.html)
CA (4) CA2795408C (cg-RX-API-DMAC7.html)
ES (1) ES2552166T3 (cg-RX-API-DMAC7.html)
MX (5) MX2012011821A (cg-RX-API-DMAC7.html)
WO (1) WO2011130194A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552166T3 (es) * 2010-04-12 2015-11-26 Supernus Pharmaceuticals, Inc. Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas
SG11201911859QA (en) 2017-06-16 2020-01-30 Beta Pharma Inc Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
CN108760719A (zh) * 2018-08-17 2018-11-06 北京理工大学 一种利用拉曼光谱分析cl-20的晶型纯度的方法
KR102927019B1 (ko) 2021-03-18 2026-02-13 슈퍼너스 파마슈티컬스, 인크. 치환된 몰폴린의 유도체 및 이의 용도
WO2023177845A1 (en) * 2022-03-18 2023-09-21 Supernus Pharmaceuticals, Inc. Process of making derivatives of substituted morpholines
WO2023248154A1 (en) * 2022-06-22 2023-12-28 Glenmark Life Sciences Limited Process for the preparation of viloxazine hydrochloride
EP4317141A1 (en) 2022-08-04 2024-02-07 Curia Spain S.A.U. Process and intermediates for the preparation of viloxazine and other 2-substituted morpholine derivatives
CN119707868A (zh) * 2023-09-27 2025-03-28 西安远大科创医药科技有限公司 一种盐酸维洛沙嗪产品杂质及其合成方法与应用
CN119707851B (zh) * 2023-09-27 2026-08-11 远大医药(西安)有限公司 一种盐酸维洛沙嗪产品杂质及其合成方法与应用
CN122422301A (zh) * 2023-12-18 2026-07-17 阿斯特罗森株式会社 (s)-维洛沙秦或其盐的改进制备方法
IT202400009022A1 (it) * 2024-04-19 2025-10-19 Cambrex Profarmaco Milano S R L Intermedi e processi per la preparazione di viloxazina

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1138405A (en) * 1966-12-28 1969-01-01 Ici Ltd Morpholine derivatives
US3712890A (en) * 1969-06-20 1973-01-23 Ici Ltd Process for making 2-aryloxymethyl morpholines
US3857839A (en) * 1969-06-20 1974-12-31 Ici Ltd For cyclising 1-aryloxy-3 beta-substituted ethylamino-2-propanols
ES411826A1 (es) * 1973-02-20 1976-01-01 Liade Sa Lab Procedimiento de obtencion de 1-ariloxi - 2 - propanolami- nas farmacologicamente activos.
JPS5188972A (en) 1975-01-29 1976-08-04 22*77 indeniruokishimechiru **4 chikanmoruhorinjudotainoseiho
JPS5283677A (en) 1976-01-01 1977-07-12 Yamanouchi Pharmaceut Co Ltd Derivative of 2-(7-indenyloxymethyl)-4-substituted morpholine
US4711887A (en) 1982-04-23 1987-12-08 Imperial Chemical Industries Plc Hydrazinopyridazine compounds
JPH06306025A (ja) * 1992-11-30 1994-11-01 Sankyo Co Ltd ジアリールアルカン誘導体
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
AU4949996A (en) * 1995-03-10 1996-10-02 Nycomed Salutar, Inc. Preparation of n-arylmethyl aziridine derivatives, 1,4,7,10-tetraazacyclododecane derivatives obtained therefrom and n-arylmethyl-ethanol-amine sulphonate esters asintermediates
AUPO565997A0 (en) * 1997-03-17 1997-04-10 Fujisawa Pharmaceutical Co., Ltd. Propanolamine derivatives
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
DE19919153A1 (de) * 1999-04-27 2000-11-02 Consortium Elektrochem Ind Herstellung von acrylierten flüssigkristallinen Verbindungen
FR2796069B3 (fr) * 1999-07-09 2001-08-24 Sanofi Synthelabo Nouveaux procedes de preparation de derives de 2-(2- arylmorpholin-2-yl)ethanol substitues, enantiomeriquement purs, et composes intermediaires utiles dans ces procedes
WO2001062236A2 (en) * 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
US20030040436A1 (en) * 2000-10-23 2003-02-27 Emerson Ralph W. Use of benzyl ester compositions for controlling non-arthropod pest populations
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7326790B2 (en) * 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
JP4210573B2 (ja) 2003-10-10 2009-01-21 花王株式会社 置換フェノキシプロパノールアミン類
JP4198183B2 (ja) * 2004-05-27 2008-12-17 ファイザー・インク 選択的ドーパミンd3アゴニストとしてのアミノピリジン誘導体
US20060118002A1 (en) * 2004-12-03 2006-06-08 Sud-Chemie Inc. Organoclay composition containing quat mixtures
EP1924572B1 (en) * 2005-09-06 2009-12-30 SmithKline Beecham Corporation Regioselective process for preparing benzimidazole thiophenes
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
CN100415709C (zh) * 2006-05-15 2008-09-03 西北大学 β-(3,4-二羟基苯基)-α-羟基丙酸冰片酯、其合成方法和用途
WO2008047388A2 (en) * 2006-10-20 2008-04-24 Ind-Swift Laboratories Limited Improved process for the preparation of ranolazine
EP2285770B1 (en) * 2008-06-02 2015-05-20 Cipla Limited Process for the synthesis of arformoterol
US20100069390A1 (en) * 2008-09-05 2010-03-18 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (ADHD)
US9296940B2 (en) * 2009-12-21 2016-03-29 Baker Hughes Incorporated Dithiazine derivatives
ES2552166T3 (es) * 2010-04-12 2015-11-26 Supernus Pharmaceuticals, Inc. Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas
TWI596088B (zh) * 2011-01-25 2017-08-21 陶氏農業科學公司 4-胺基-6-(經取代的苯基)吡啶甲酸酯及6-胺基-2-(經取代的苯基)-4-嘧啶羧酸酯之芳烷酯以及其等作為除草劑之用途
TWI610929B (zh) * 2012-11-21 2018-01-11 拉夸里亞創藥股份有限公司 多形體形式

Similar Documents

Publication Publication Date Title
JP2023506147A5 (cg-RX-API-DMAC7.html)
EP4494703A3 (en) Therapeutic solid dosage forms
JP2017178948A5 (cg-RX-API-DMAC7.html)
WO2020113213A3 (en) Cyclic pantetheine derivatives and uses thereof
JP2016147915A5 (cg-RX-API-DMAC7.html)
JP2003531157A5 (cg-RX-API-DMAC7.html)
EP4537828A3 (en) Phospholipid compounds and uses thereof
NO20062051L (no) Farmasoytisk virkestoffinneholdende formulering med belegg
JP2020519708A5 (cg-RX-API-DMAC7.html)
GEP20043285B (en) Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections
EP4269549A3 (en) Skin cleansing compositions
JP2018521007A5 (cg-RX-API-DMAC7.html)
JP2022132411A5 (cg-RX-API-DMAC7.html)
WO2009004792A1 (ja) スルホンアミド化合物及びその結晶
JP2006507295A5 (cg-RX-API-DMAC7.html)
JP2018021060A5 (cg-RX-API-DMAC7.html)
NO20083790L (no) Nye terapeutiske kombinasjoner for behandling eller forebygging av psykotiske lidelser
EP1609473A8 (en) Use of acetyl-d-aminoglycosamine in treatment of local lesions and systematic symptoms related to infections of virus or bacteria
MX2022006104A (es) Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma.
IL295014B1 (en) A pharmaceutical preparation containing 5-(-6,3-dibromo-H9-carbazol-9-yl)-N,N,N-trimethylpentan-1-iminium or the pharmaceutical salt is suitable for use in the treatment of angiolipoma
EP4335509A3 (en) Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases
JP2021535170A5 (cg-RX-API-DMAC7.html)
JP2008513426A5 (cg-RX-API-DMAC7.html)
MX2019014201A (es) Composicion farmaceutica y forma de dosificacion farmaceutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenza mida, proceso para su preparacion, metodos de tratamiento y usos de las mismas.
JP2016175884A5 (cg-RX-API-DMAC7.html)